Drugs / ASP8302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03361540 | Nov 2017 → Apr 2018 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03702777 | Nov 2018 → Apr 2020 | urinary bladder, atony of | Astellas Pharma Europe B.V. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03702777 ↗ |
| Modality | Small molecule | — CHEMBL6068539 ↗ |
| Route | Oral | “ASP8302 will be administered orally.” NCT03361540 ↗ |